RU2003134636A - Ef-tu связанные вещества в качестве антибактериального средства - Google Patents

Ef-tu связанные вещества в качестве антибактериального средства Download PDF

Info

Publication number
RU2003134636A
RU2003134636A RU2003134636/13A RU2003134636A RU2003134636A RU 2003134636 A RU2003134636 A RU 2003134636A RU 2003134636/13 A RU2003134636/13 A RU 2003134636/13A RU 2003134636 A RU2003134636 A RU 2003134636A RU 2003134636 A RU2003134636 A RU 2003134636A
Authority
RU
Russia
Prior art keywords
amino acids
substances
antibacterial agent
domain
use according
Prior art date
Application number
RU2003134636/13A
Other languages
English (en)
Russian (ru)
Inventor
Франк МАЙЕР (DE)
Франк МАЙЕР
Original Assignee
Новологикс Гмбх (De)
Новологикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129870A external-priority patent/DE10129870A1/de
Application filed by Новологикс Гмбх (De), Новологикс Гмбх filed Critical Новологикс Гмбх (De)
Publication of RU2003134636A publication Critical patent/RU2003134636A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2003134636/13A 2001-04-30 2002-04-22 Ef-tu связанные вещества в качестве антибактериального средства RU2003134636A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10121145.7 2001-04-30
DE10121145 2001-04-30
DE10129870.6 2001-06-21
DE10129870A DE10129870A1 (de) 2001-04-30 2001-06-21 Antibakterielles Mittel

Publications (1)

Publication Number Publication Date
RU2003134636A true RU2003134636A (ru) 2005-04-20

Family

ID=26009202

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003134636/13A RU2003134636A (ru) 2001-04-30 2002-04-22 Ef-tu связанные вещества в качестве антибактериального средства

Country Status (17)

Country Link
EP (1) EP1397157A2 (fr)
JP (1) JP2004534016A (fr)
CN (1) CN1298739C (fr)
AU (1) AU2002302555B2 (fr)
BG (1) BG108399A (fr)
BR (1) BR0209282A (fr)
CA (1) CA2445995A1 (fr)
CZ (1) CZ20033271A3 (fr)
EE (1) EE200300530A (fr)
HU (1) HUP0401586A3 (fr)
IL (1) IL158627A0 (fr)
MX (1) MXPA03009954A (fr)
NZ (1) NZ529662A (fr)
PL (1) PL366836A1 (fr)
RU (1) RU2003134636A (fr)
SK (1) SK14792003A3 (fr)
WO (1) WO2002087554A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229645A1 (de) * 2002-07-02 2004-05-19 Kuchenreuther, Ulrich, Dr. Zellaufschluss von Bakterien
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (fr) 2009-07-31 2017-06-06 Thar Pharma, Llc Procede de cristallisation et biodisponibilite
WO2012071517A2 (fr) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Nouvelles formes cristallines
CN105218668B (zh) * 2015-10-30 2020-03-24 山东农业大学 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用
WO2017208070A1 (fr) 2016-05-31 2017-12-07 Grünenthal GmbH Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466251A1 (fr) * 1990-07-10 1992-01-15 Gist-Brocades N.V. Mutants résistant à l'elfamycine
AU2717699A (en) * 1998-01-23 1999-08-09 Akzo Nobel N.V. Ef-tu mrna as a marker for viability of bacteria
US6451556B1 (en) * 1998-12-21 2002-09-17 Smithkline Beecham Corporation EF-Tu

Also Published As

Publication number Publication date
SK14792003A3 (sk) 2004-07-07
WO2002087554A3 (fr) 2003-01-30
NZ529662A (en) 2006-08-31
CA2445995A1 (fr) 2002-11-07
CN1298739C (zh) 2007-02-07
PL366836A1 (en) 2005-02-07
AU2002302555B2 (en) 2007-08-23
BR0209282A (pt) 2004-07-27
HUP0401586A3 (en) 2005-06-28
JP2004534016A (ja) 2004-11-11
IL158627A0 (en) 2004-05-12
EE200300530A (et) 2004-04-15
BG108399A (bg) 2004-08-31
CZ20033271A3 (en) 2004-06-16
CN1518455A (zh) 2004-08-04
EP1397157A2 (fr) 2004-03-17
HUP0401586A2 (hu) 2004-11-29
WO2002087554B1 (fr) 2005-01-27
WO2002087554A2 (fr) 2002-11-07
MXPA03009954A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
Sousa et al. Collagen from Atlantic cod (Gadus morhua) skins extracted using CO2 acidified water with potential application in healthcare
Steinert et al. Structural features of keratin intermediate filaments
Selsted et al. Determination of the disulfide array in the human defensin HNP-2: a covalently cyclized peptide
Engel et al. Electron microscopy and other physical methods for the characterization of extracellular matrix components: laminin, fibronectin, collagen IV, collagen VI, and proteoglycans
Erickson et al. Fibronectin molecule visualized in electron microscopy: a long, thin, flexible strand.
AU2008280151B2 (en) Antibiotic peptides
US7488792B2 (en) Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US7482328B2 (en) Antimicrobial polypeptide and utilization thereof
CA2146667A1 (fr) Peptides possedant un pouvoir neutralisateur et une grande affinite pour les lipopolysaccharides
Oren et al. A comparative study on the structure and function of a cytolytic α‐helical peptide and its antimicrobial β‐sheet diastereomer
AU759636B2 (en) Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
CN116947999A (zh) 小分子抗菌多肽、制备方法及其用途
Siriwardena et al. Stereorandomization as a method to probe peptide bioactivity
de Haas et al. Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS
Matharu et al. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease
CN117024552A (zh) 小分子抗菌多肽、制备方法及其用途
RU2003134636A (ru) Ef-tu связанные вещества в качестве антибактериального средства
Boullet et al. Small antimicrobial peptide with in vivo activity against sepsis
Serizawa et al. Affinity-based release of polymer-binding peptides from hydrogels with the target segments of peptides
Frick et al. Identification of a novel protein promoting the colonization and survival of Finegoldia magna, a bacterial commensal and opportunistic pathogen
Otvos Jr et al. Chimeric antimicrobial peptides exhibit multiple modes of action
DE69132813D1 (de) Genetisches igfbp-5 rodierendes material
Bahatheg et al. Short tryptamine-based peptoids as potential therapeutics for microbial keratitis: Structure-function correlation studies
Ohno LPS binding proteins in granulocyte lysosomes
Braun et al. Stable acetaldehyde adducts: structural characterization of acetaldehyde adducts of human hemoglobin N‐terminal β‐globin chain peptides